Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210219 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04210219 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 85 participants.
The verdict
NCT04210219, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in Part 2.
Interventions
- DRUG JNJ-64264681
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210219
The ClinicalTrials.gov registry entry for NCT04210219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-64264681 is the first listed.
NCT04210219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210219 about?
NCT04210219 is a clinical study titled "A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia". The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in Part 2.
What is the current status of trial NCT04210219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-07-02. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT04210219?
The interventions under investigation include: JNJ-64264681 (DRUG).
Who is sponsoring clinical trial NCT04210219?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.